Swiss National Bank
INDV icon

Swiss National Bank’s Indivior Pharmaceuticals INDV Stock Holding History

Swiss National Bank’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.53M Sell
207,931
-2,100
-1% -$76.2K ﹤0.01% 1125
2026
Q1 		$6.4M Buy
210,031
+37,700
+22% +$1.25M ﹤0.01% 1206
2025
Q4 		$6.18M Sell
172,331
-21,100
-11% -$644K ﹤0.01% 1235
2025
Q3 		$4.66M Buy
193,431
+2,900
+2% +$60.7K ﹤0.01% 1370
2025
Q2 		$2.83M Sell
190,531
-2,642
-1% -$30.8K ﹤0.01% 1601
2025
Q1 		$1.81M Sell
193,173
-23,622
-11% -$248K ﹤0.01% 1825
2024
Q4 		$2.78M Sell
216,795
-5,440
-2% -$56K ﹤0.01% 1672
2024
Q3 		$2.19M Sell
222,235
-4,407
-2% -$51.6K ﹤0.01% 1810
2024
Q2 		$3.55M Sell
226,642
-1,861
-0.8% -$33.6K ﹤0.01% 1485
2024
Q1 		$4.89M Sell
228,503
-2,563
-1% -$48.1K ﹤0.01% 1311
2023
Q4 		$3.49M Sell
231,066
-56,831
-20% -$1.01M ﹤0.01% 1505
2023
Q3 		$6.26M Buy
287,897
+2,727
+1% +$62.2K ﹤0.01% 1137
2023
Q2 		$6.6M Buy
+285,170
New +$6.54M ﹤0.01% 1139

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Swiss National Bank's INDV Position: Q2 2026 in Review

Swiss National Bank reduced its Indivior Pharmaceuticals (INDV) stake by 1% in Q2 2026, selling an estimated $76.2K and leaving 207,931 shares worth $8.53M. The position accounts for ﹤0.01% of the portfolio, ranked #1125.

Swiss National Bank first reported a position in INDV in Q2 2023 and has held it in 13 quarters since. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Swiss National Bank held 207,931 shares of Indivior Pharmaceuticals worth $8.53M as of Q2 2026.
  • Swiss National Bank sold 2,100 Indivior Pharmaceuticals shares in Q2 2026, an estimated $76.2K.
  • Indivior Pharmaceuticals made up ﹤0.01% of Swiss National Bank's portfolio in Q2 2026, its #1125 holding.
  • Swiss National Bank first reported a position in Indivior Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • 338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.